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ABSTRACT
Objectives Th17 cells are an effector T-cell 
population that plays a role in chronic inflammatory 
conditions and is dependent on IL-23 for their survival 
and expansion. More recently, a genetic association 
was discovered between polymorphisms in the gene 
coding for the IL-23 receptor and spondyloarthritis. 
This study aimed to evaluate the role of Th17-
associated cytokines in spondyloarthritis pathogenesis 
by measuring their levels in the joints and circulation 
as well as correlating them with disease activity 
parameters.
Methods Paired synovial fl uid (SF), serum and synovial 
biopsies were obtained from 30 non-PsA (psoriatic 
arthritis) spondyloarthritis, 22 PsA and 22 rheumatoid 
arthritis (RA) patients. IL-17, IL-23 and CCL20 were 
measured by ELISA in the SF and serum of patients and 
correlated with systemic and local parameters of disease 
activity.
Results Concentrations of CCL20, a major Th17-
attracting chemokine, tended to be higher in the joints 
of RA than in spondyloarthritis patients. Interestingly, 
levels of CCL20 were markedly higher in SF as opposed 
to serum. In addition, there was a remarkable association 
between the expression of the Th17 cytokine system and 
the presence of intimal lining layer hyperplasia in RA. Also 
in the serum, there was a tendency for higher IL-23 levels 
in RA, which correlated strongly with disease activity 
parameters.
Conclusions Th17-related cytokines are expressed 
in joints of spondyloarthritis as well as RA patients. 
IL-23 levels, however, correlate with disease activity 
parameters in RA only. These results point towards a 
differential regulation of the Th17 cytokine system in 
spondyloarthritis compared with RA.
Spondyloarthritis is a chronic inﬂ ammatory dis-
ease that affects approximately 0.5% of the west-
ern population. The symptoms usually start in the 
third decade of life, and are primarily the result of 
the presence of inﬂ ammation in the spine (spon-
dylitis) and joints (arthritis), sometimes together 
with inﬂ ammation of the eye (anterior uveitis), gut 
(ileitis or colitis) and skin (psoriasis). The aetiology 
of the disease is unknown, but family studies have 
shown that there is an important genetic contribu-
tion to the disease.1 Apart from HLA-B27, recent 
studies demonstrated that polymorphisms in the 
gene coding for the IL-23 receptor are also strongly 
linked to the development of spondyloarthritis.2
IL-17-producing T helper (Th17) cells are a 
recently discovered effector T-lymphocyte subset,3 
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which plays a critical role in several animal mod-
els of chronic inﬂ ammatory diseases, such as 
 collagen-induced arthritis,4 T-cell-mediated colitis5 
and experimental uveitis.6
In contrast to other effector T-cell subsets, Th17 
cells express the IL-23 receptor on their membrane 
and are dependent on this cytokine for their sur-
vival and expansion.7
In addition, Th17 cells, unlike other effector 
T-cell subsets, express the chemokine receptor, 
CCR6, on their membrane,8 which can be acti-
vated by its cognate ligand, CCL20.9 Interfering 
with IL-23R or CCR6 activation has been shown to 
be an effective treatment strategy in different ani-
mal models of arthritis.4 10 Th17 cells are also very 
likely to play an important role in human chronic 
inﬂ ammatory conditions, because polymorphisms 
in the IL-23 receptor are closely associated with 
the development of Crohn’s disease11 as well as 
psoriasis.12 Furthermore, Th17 cells are enriched 
in the inﬂ ammatory lesions in both diseases,13 
14 and treatment of patients with anti-IL-23 p40, 
which blocks both IL-12 and IL-23, has a beneﬁ cial 
effect on the disease course in Crohn’s disease15 
and psoriasis.16
Considering the genetic association between 
IL-23 receptor polymorphisms and spondyloar-
thritis2 as well as the established role of Th17 
cells in spondyloarthritis-related inﬂ ammatory 
diseases,4–6 15 16 we wanted to assess the potential 
role of the Th17 cytokine system in spondyloar-
thritis joint inﬂ ammation. Therefore we measured 
the concentration of IL-17, IL-23 and CCL20 in 
the joints and serum of spondyloarthritis patients, 
compared it with rheumatoid arthritis (RA) patients 
and related it to local and systemic parameters of 
disease activity.
PATIENTS AND METHODS
Patients
The ﬁ rst study population consisted of paired sam-
ples of synovial ﬂ uid (SF), synovial biopsies and 
serum from 52 spondyloarthritis patients fulﬁ lling 
the European Spondyloarthropathy Study Group 
classiﬁ cation criteria for  spondyloarthritis17 and 
22 RA patients fulﬁ lling the American College 
of Rheumatology Classiﬁ cation criteria for RA.18 
The spondyloarthritis cohort consisted of 22 
patients with psoriatic arthritis (PsA) fulﬁ lling in 
addition the CASPAR criteria19 and 30 patients 
with non-psoriatic arthritis spondyloarthritis 
(non-PsA SpA) (six ankylosing spondylitis (AS) 
patients, 22 undifferentiated spondyloarthritis 
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(USpA) patients and two patients with reactive arthritis 
(ReA)). SF and synovial biopsies were obtained by needle 
arthroscopy of the knee as previously described.20 All patients 
had a clinical joint effusion at the time of arthroscopy. In 
addition, serum samples were collected from eight healthy 
control (HC) subjects (mean age 27.63 years; SEM 1.15; six 
men and two women). SF and serum samples were stored 
at –20°C. Synovial biopsies were formalin ﬁ xed or snap fro-
zen in liquid nitrogen.
The second study population consisted of 15 spondyloarthri-
tis patients (seven with PsA and eight with non-PsA SpA (seven 
AS patients and one USpA patient)) with indications for TNF 
blockade treatment. From these patients, serum samples were 
collected before and after 12 weeks of treatment with inﬂ iximab 
(5 mg/kg at weeks 0, 2 and 6). 
Written informed consent was given by all the patients before 
inclusion in the study, as approved by the Ethics Committee of 
the Ghent University Hospital.
Enzyme-linked immunosorbent assay
Synovial ﬂ uid and serum IL-17 and CCL20 were measured 
with commercial sandwich ELISA following the manufactur-
er’s instructions (DuoSet ELISA Development System; R&D 
Systems, Abingdon, UK). For CCL20 measurements, the SF 
was diluted 20-fold in 1% bovine serum albumin in phosphate 
buffered saline. IL-23 was measured by a commercial sandwich 
ELISA following the manufacturer’s instructions  (eBioscience, 
San Diego, California, USA). The assay consists of a cap-
ture antibody directed against the human IL-23 p19 subunit 
and a biotinylated detection antibody recognising the human 
IL-12/IL-23 p40 subunit.
Histopathology and immunohistochemistry
After ﬁ xation in 4% formaldehyde, the biopsies were embedded 
in parafﬁ n and cut into 4 μm sections. The procedure for histo-
logical and immunohistochemical analysis of the different mark-
ers was extensively described and validated previously.21 Brieﬂ y, 
parafﬁ n sections were deparafﬁ nised and either directly stained 
with haematoxylin and eosin for routine histology or processed 
for immunohistochemistry. T cells were detected with anti-CD3 
(Clone UCHT1; Dako, Glostrup, Denmark) and B lymphocytes 
with anti-CD20 (Clone L26; Dako). After incubation with the 
primary antibody, the sections were sequentially incubated with 
a biotinylated second antibody, a streptavidin–horse radish per-
oxidase link, and ﬁ nally with amino-ethyl-carbazole substrate 
as chromogen (Dako).
Microscopic analysis
The histopathological characteristics of the synovial membrane 
and the immunohistochemical stainings were assessed by semi-
quantitative scoring (0–3) by two independent observers, as 
extensively described and validated previously.21
The scores never differed by more than one score and the 
mean of both observers was used in the case of one-point dis-
cordance. The observers were blinded for diagnosis and the 
slides were evaluated in random order.
Statistics
All analyses were performed using SPSS software. Non-
parametric data were analysed using the Kruskal–Wallis or the 
Mann–Whitney U test for comparisons between groups. The 
paired Wilcoxon signed ranks test was used in case of paired 
non-parametric data.
Normally distributed data were analysed using the one-way 
analysis of variance, the independent-samples t test and the 
paired-samples t test. Correlation coefﬁ cients were calculated 
with the Spearman correlation coefﬁ cient test.
RESULTS
We ﬁ rst evaluated whether the arthritis cohorts showed any dif-
ferences in the degree of inﬂ ammatory activity at the time of 
sampling. The number of polymorphonuclear cells in the joint 
ﬂ uid and the degree of cellular inﬁ ltration of the synovial mem-
brane were considered as local parameters of joint inﬂ ammation, 
whereas C-reactive protein (CRP) and erythrocyte sedimenta-
tion rate (ESR) levels were regarded as systemic parameters of 
inﬂ ammation. As shown in table 1 the degree of local as well as 
systemic inﬂ ammatory activity was not signiﬁ cantly different 
between the cohorts. This indicates that eventual differences in 
the levels of inﬂ ammatory mediators between the RA, non-PsA 
SpA and PsA cohorts would be the result of genuine disease-
speciﬁ c traits rather than merely differences in the intensity of 
inﬂ ammation.
CCL20 levels are elevated in the synovial fl uid of non-PsA SpA, 
PsA and RA patients compared to serum
We next measured steady-state SF levels of IL-17 and IL-23.
The concentration of IL-17 in the SF tended to be higher in non-
PsA SpA patients compared with RA and PsA patients (non-PsA 
SpA mean 43.92 pg/ml; SEM 17.07 vs RA 29.41 pg/ml; SEM 10.03 
vs PsA 31.68 pg/ml; SEM 16.81 (p=0.386)). In contrast, the con-
centration of IL-23, the major Th17 driving cytokine, was similar 
in the joints of RA, non-PsA SpA and PsA patients (p=0.816).
In contrast, the concentration of the Th17 attracting chemokine, 
CCL20, tended to be higher in RA patients than in non-PsA SpA 
and PsA patients (RA mean 2340.31 pg/ml; SEM 742.41 vs non-
PsA SpA 876.34 pg/ml; SEM 390.88 vs PsA 1186.71 pg/ml; SEM 
570.15 (p=0.079)).
A true chemotactic role for CCL20 in attracting immune cells 
to the joints of arthritis patients was suggested by the fact that 
the concentration was strongly elevated in the SF in compari-
son to the serum in RA (mean 255.08-fold; SEM 59.33; p=0.001), 
non-PsA SpA (mean 242.85-fold; SEM 95.11; p<0.001) and PsA 
(mean 170.99-fold; SEM 78.09; p<0.001) (ﬁ gure 1).
Synovial fl uid CCL20 correlates with joint infl ammation in 
spondyloarthritis and RA
Considering the pathogenic role of the IL-23/IL-17 cytokine axis in 
driving joint inﬂ ammation in several arthritic mouse models,22–24 
we evaluated if the presence of IL-23 or IL-17 protein in the joints 
of spondyloarthritis patients was related to features of joint 
inﬂ ammation. In contrast with previous reports of observations 
in airway inﬂ ammation25–27 we did not ﬁ nd a signiﬁ cant rela-
tionship between local IL-23 or IL-17 levels and SF polymorpho-
nuclear count in RA, PsA or non-PsA SpA patients (table 2).
Remarkably, SF CCL20 levels correlated strongly with SF poly-
morphonuclear numbers in RA (r 0.498; p=0.021), PsA (r 0.639; 
p=0.006) and non-PsA SpA (r 0.654; p=0.001).
On histopathological evaluation of the synovial tissue, SF 
IL-17 concentration was closely correlated with the degree of 
intimal lining layer hyperplasia in RA (r 0.583; p=0.009), but not 
in spondyloarthritis patients.
This was also the case for SF IL-23 (r 0.657, p=0.002) and SF 
CCL20 (r 0.463, p=0.046). Furthermore, SF CCL20 strongly cor-
related with global synovial cellular inﬁ ltration in RA patients (r 
0.607; p=0.006), but not in spondyloarthritis patients (table 2).
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Table 1 Demographic, clinical, biochemical and histopathological data of the patient cohorts
(A) First study population RA non-PsA SpA PsA p Value
Number of patients (n) 22 30 22
Age (years) 56.14±2.78 34.43±2.90 43.86±3.36
Gender (male/female)    6/16   18/12   12/10
Disease duration (years) 8.91±2.02 5.26±1.43 4.30±0.95
Rheumatoid factor (% present) 68 13 9
NSAID treatment (n) 16 20 11
Prednisone treatment (n) 10 2 1
DMARD treatment (n) 18 12 8
Lefl unomide (n) 3 0 1
Methotrexate (n) 13 2 3
Adalimumab (n) 1 0 0
Salazopyrine (n) 1 9 3
Salazopyrine + methotrexate (n) 0 1 1
SJC 6.91±1.23 4.07±0.95 2.38±0.72 0.001
CRP (mg/dl) 4.03±1.37 5.42±1.25 2.86±0.90 0.308
ESR (mm/h) 35.00±4.88 37.34±6.48 24.60±4.22 0.421
SF PMN count (cells/mm2) 8573.49±2292.67 5748.45±1188.96 8926.61±2668.34 0.921
Synovial tissue T-cell infi ltration (SQ-score) 1.5 (0–2)    1 (0–3)    1 (0–2) 0.360
 Synovial tissue intimal lining layer hyperplasia (SQ-score)    1 (1–3)    1 (1–3)    1 (1–3) 0.603
 Synovial tissue global cellular infi ltration (SQ-score)    2 (0–3)    2 (0–3) 1.5 (0–3) 0.815
(B) Infl iximab treatment second study population Total SpA
No of patients (n) 15
Age (years) 47.93±2.60
Gender (male/female)   11/4
Disease duration (years) 8.67±1.72
NSAID treatment (n) 13
Before After p Value
SJC 7.3±1.4 1.1±0.3 <0.001
CRP (mg/dl) 2.5±0.6 1.2±0.6 <0.05
ESR (mm/h) 20.0±4.1 8.0±1.8 <0.001  
Quantitative data are represented as means±SEM, whereas semiquantitative scores (SQ-scores) are indicated as medians (ranges). Table (A) represents the data of the fi rst study 
population, while table (B) shows the results for the infl iximab serum second study population.
CRP, C-reactive protein; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; NSAID, non-steroidal anti-infl ammatory drug; PMN, polymorphonuclear; 
PsA, psoriatic arthritis; RA, rheumatoid arthritis; SF, synovial fl uid; SJC, swollen joint count; SpA, spondyloarthritis.
Figure 1 (A) IL-17, (B) IL-23 and 
(C) CCL20 were measured by sandwich 
ELISA in the syniovial fl uid (SF) of 22 
rheumatoid arthritis, 30 non-psoriatic 
arthritis (PsA) spondyloarthritis (SpA) 
and 22 PsA patients of the fi rst study 
population. The CCL20 results in the 
paired serum samples of these (D) 30 
non-PsA SpA and (E) 22 PsA patients 
are also depicted. The bars represent 
means±SEM.
Serum IL-23 levels strongly correlate with disease 
activity in RA
In serum, we detected similar levels of IL-17 and CCL20 in 
HC, RA, PsA and non-PsA SpA patients (p=0.358 and p=0.143, 
respectively).
Overall, the interpatient variability of the serum IL-17 and 
serum CCL20 concentration was rather large and in the major-
ity of the patient sera IL-17 and CCL20 levels were either 
very close to or below the detection limit of the assay. Also 
no signiﬁ cant differences (p=0.320) were observed for serum 
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by inﬂ iximab treatment in 15 patients (eight non-PsA SpA and 
seven PsA).
As expected, TNF blockade was effective in reducing systemic 
measures of inﬂ ammation in this additional patient cohort. 
CRP (p<0.05), ESR (p<0.001) and swollen joint count (p<0.001) 
decreased signiﬁ cantly after 12 weeks of treatment (p<0.05) 
(table 1 (B)). In contrast, TNF blockade did not signiﬁ cantly inﬂ u-
ence serum CCL20 (Δmean −2.12 pg/ml; ΔSEM 1.93; p=0.307), 
serum IL-17 (Δmean −1.56 pg/ml; ΔSEM 5.07; p=1.000) or serum 
IL-23 (Δmean −0.75 pg/ml; ΔSEM 4.65; p: 0.955) (ﬁ gure 2). Also 
when non-PsA SpA and PsA patients were analysed separately 
we found no signiﬁ cant inﬂ uence of inﬂ iximab treatment on 
serum CCL20, IL-17 and IL-23 levels (data not shown).
To acknowledge that this TNF independence was not merely 
the result of instability of the cytokine serum levels over time, 
we also investigated serum samples of 10 spondyloarthritis 
patients (ﬁ ve non-PsA SpA and ﬁ ve PsA) before and after 12 
weeks of placebo treatment (data not shown). The 12-week 
time period did not inﬂ uence CCL20 (Δmean −2.65 pg/ml; 
ΔSEM 5.71; p=0.508), IL-17 (Δmean −1.75 pg/ml; ΔSEM 16.68; 
p=0.686), and IL-23 (Δmean −1.29 pg/ml; ΔSEM 10.84; p=0.575) 
IL-23 levels between the cohorts, although these levels tended 
to be slightly higher in RA patients (mean 50.92 pg/ml; SEM 
19.25) compared with HC (mean 15.10 pg/ml; SEM 4.90), non-
PsA SpA (mean 16.87 pg/ml; SEM 3.45) and PsA (mean 11.87 
pg/ml; SEM 2.97) patients (ﬁ gure 2). In line with a previous 
report,28 serum IL-17 levels in non-PsA SpA patients, as in RA 
and PsA patients, did not correlate with systemic parameters 
of disease activity. In contrast; serum IL-23 levels in RA, but 
not in non-PsA SpA and PsA, strongly correlated with swollen 
joint count (r 0.697; p=0.004), ESR (0.665; p=0.013), serum CRP 
 levels (r 0.578; p=0.030) as well as with the disease activity in 
28 joints (DAS28) score index (r 0.627; p=0.039). Serum CCL20 
in spondyloarthritis, as in RA, did not correlate with systemic 
disease activity parameters (table 3).
Serum CCL20, IL-17 and IL-23 are not infl uenced by 
TNF blockade in spondyloarthritis
In order to explore further the potential link between inﬂ am-
mation and the IL-23/IL-17 cytokine system in spondylo-
arthritis we measured the serum concentration of CCL20, 
IL-17 and IL-23 before and after 12 weeks of TNF blockade 
Figure 2 (A) IL-17, (B) IL-23 and 
(C) CCL20 were measured by sandwich 
ELISA in the serum of 22 rheumatoid 
arthritis (RA), 30 non-psoriatic arthritis 
(PsA) spondyloarthritis (SpA) and 
22 PsA patients of the fi rst study 
population and eight healthy controls 
(HC). (D–F) The same mediators were 
also measured in the serum before and 
after 12 weeks of TNF blockade in 15 
spondyloarthritis patients (eight with 
non-PsA SpA and seven with PsA). The 
bars represent means±SEM.
Table 2 Correlation analysis of SF levels of indicated mediators and local parameters of joint infl ammation 
for the fi rst study population.
SF IL-17 SF IL-23 SF CCL20
 r p Value r p Value r p Value
RA
 SF PMN count (cells/mm2) 0.278 0.211 0.189 0.400 0.489 0.021
 Synovial tissue T-cell infi ltration 0.185 0.463 0.064 0.801 0.453 0.059
 Synovial tissue intimal lining layer hyperplasia 0.583 0.009 0.657 0.002 0.463 0.046
 Synovial tissue global cellular infi ltration 0.039 0.873 0.267 0.269 0.607 0.006
Non-PsA SpA
 SF PMN count (cells/mm2) 0.209 0.351 −0.211 0.346 0.654 0.001
 Synovial tissue T-cell infi ltration 0.018 0.935 0.013 0.955 0.208 0.353
 Synovial tissue intimal lining layer hyperplasia −0.043 0.850 0.206 0.357 0.113 0.616
 Synovial tissue global cellular infi ltration −0.121 0.592 0.153 0.498 0.032 0.888
PsA
 SF PMN count (cells/mm2) 0.435 0.081 0.070 0.790 0.639 0.006
 Synovial tissue T-cell infi ltration −0.166 0.539 0.427 0.099 −0.276 0.301
 Synovial tissue intimal lining layer hyperplasia 0.159 0.556 0.159 0.556 −0.483 0.058
 Synovial tissue global cellular infi ltration −0.027 0.921 0.117 0.667 0.061 0.821
All correlations were calculated with the Spearman correlation coeffi cient test.
PMN, polymorphonuclear; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SF, synovial fl uid; SpA, spondyloarthritis.
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Intimal lining layer hyperplasia results from the accumula-
tion of  ﬁ broblast-like as well as macrophage-like synovio-
cytes in the lining layer and is a common feature of chronic 
synovitis.38 IL-17 has been shown to activate ﬁ broblast-like 
synoviocytes.39
Why the association between IL-23/IL-17 and lining hyperpla-
sia was not present in spondyloarthritis patients, in whom lining 
layer hyperplasia was as pronounced as in the RA patients, is 
not clear at present.
The slightly elevated serum IL-23 levels in RA patients 
strongly correlated with disease activity parameters. In spon-
dyloarthritis patients, by contrast, no correlations with CRP, 
ESR or swollen joint count were observed. IL-23 is a het-
erodimeric cytokine that is composed of an IL-12 p40 subunit 
together with an IL-23 p19 subunit, and is primarily produced 
by dendritic cells and monocytes.40 The production of the 
cytokine, which is dependent on the canonical nuclear factor 
κB signalling pathway,41 is promoted by several factors includ-
ing the triggering of innate immune receptors such as Toll-like 
receptor,40 dectin-142 or nucleotide oligomerisation domain 2 
triggering43 as well as by the CD40 ligand.40 In line with the 
inﬂ ammatory nature of this cytokine, serum IL-23 levels in 
RA patients are decreased after TNF blockade.44 These obser-
vations suggest that IL-23 could be a valuable inﬂ ammatory 
biomarker in RA. This decrease after TNF blockade was not 
observed in our spondyloarthritis patient cohort treated with 
inﬂ iximab.
On the other hand, we found a trend towards slightly higher 
concentrations of IL-17 in the SF in non-PsA SpA patients com-
pared with RA and PsA patients.
In conclusion, our data point towards a potentially important 
role for the Th17 cytokine system in joint inﬂ ammation and 
remodelling in chronic arthritis.
Furthermore, we found that the regulation of the Th17 
cytokine system may be different between RA and spondylo-
arthritis synovitis. Indeed, a series of recent reports found a 
strong association between polymorphisms in the IL-23 recep-
tor and the occurrence of spondyloarthritis2–4 as well as other, 
spondyloarthritis- related, seronegative chronic inﬂ ammatory 
diseases,13 14 but not of RA.45 These results warrant further 
serum levels. Also when non-PsA SpA and PsA patients were 
analysed separately we found no signiﬁ cant inﬂ uence of time on 
serum CCL20, IL-17 and IL-23 levels.
DISCUSSION
The IL-23/IL-17 axis has been shown to be a major pro-
inﬂ ammatory pathway in several chronic inﬂ ammatory 
diseases.6–8 17 18 22–24
In this study we evaluated the relationship between the local 
and systemic expression of key mediators of this pathway and 
parameters of inﬂ ammation in spondyloarthritis patients.
A ﬁ rst ﬁ nding of this study was that CCL20 levels strongly 
correlated with SF polymorphonuclear numbers in RA and spon-
dyloarthritis. These data point towards a potentially important 
role for CCL20 as a mediator of joint inﬂ ammation in spondy-
loarthritis patients. CCL20 is produced locally in the joint by 
chondrocytes upon exposure to mechanical stress,29 by synovial 
ﬁ broblasts upon stimulation with proinﬂ ammatory cytokines30 
and by Th17 cells.31 CCL20 in turn, attracts immature myeloid 
dendritic cells32 as well as naive B cells33 and effector memory T 
cells, especially Th17 cells.34
In addition, Ruth et al35 showed that CCL20 accounts for 
approximately 40% of the chemotactic activity of the RA SF 
for monocytes. Also, blocking CCR6, the sole receptor for 
CCL20, protects mice from T-cell-mediated arthritis.10 In addi-
tion, serum CCL20 was not elevated in comparison with HC 
and was not modulated by TNF blockade in spondyloarthritis 
patients, which points towards a TNFα independent role for 
CCL20. Future studies will have to address the in-vivo role of 
the CCL20–CCR6 axis in the initiation and perseveration of 
inﬂ ammation in the joint, but also the gut, of spondyloarthritis 
patients.
In contrast to SF CCL20 in spondyloarthritis, SF IL-17 and 
IL-23 were not signiﬁ cantly increased compared with serum and 
did not correlate with local inﬂ ammatory parameters.
Another ﬁ nding was that the degree of intimal lining layer 
hyperplasia in RA patients was strongly associated with IL-17, 
IL-23 and CCL20 levels in the joint.
Of note, also in the skin of psoriasis patients, Th17 responses 
are strongly correlated with epidermal hyperplasia.36 37 
Table 3 Correlation analysis of serum levels of indicated mediators and systemic parameters of disease 
activity for the fi rst population
Serum IL-17 Serum IL-23 Serum CCL20
 r p Value r p Value r p Value
RA
 SJC −0.224 0.388 0.697 0.004 0.057 0.829
 ESR −0.041 0.884 0.665 0.013 0.432 0.108
 CRP 0.010 0.971 0.578 0.030 0.464 0.081
 DAS28 −0.262 0.388 0.627 0.039 0.126 0.681
Non-PsA SpA
 SJC −0.282 0.215 −0.155 0.514 −0.388 0.082
 ESR −0.228 0.334 −0.001 0.997 0.139 0.558
 CRP −0.057 0.807 −0.089 0.708 0.193 0.401
 DAS28 NA NA NA NA NA NA
PsA
 SJC 0.085 0.728 0.177 0.470 0.022 0.930
 ESR 0.267 0.284 0.009 0.972 0.212 0.398
 CRP 0.150 0.539 −0.099 0.687 0.177 0.470
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